Skip to content

Climb Bio

US · CLYM #3610 by market cap Listed 2021
9.19 -0.09 -0.97%
Periodic snapshot; not a real-time feed. · 2026-11-20 19:30

Price chart

Pre-market 9.01 -2.91%
After-hours 9.03 -1.76%
17.848.819.192026-05-262026-11-20
MA5MA10MA20MA60
— MA5 — MA10 — MA20 — MA60
Reader sentiment Are you bullish or bearish on CLYM?

Anonymous reader poll. Unscientific, not investment advice.

✦ StockVane Quant Insights how this is computed

Quant Sentiment Neutral
  • Recent price momentum is +192.6% on average (3-month/1-year).
  • Main-fund capital flow has been a net outflow over the last 45 sessions.
  • Short interest has risen to 18.5% of float.
  • Analyst tilt is Buy.
Quant Technical Outlook Bearish
  • Price is below its 20-day average and below its 60-day average.
  • The 20-day average is below the 60-day average, a short-term downtrend.
Quant Rating, last 30 days A → D

Computed by a StockVane algorithm from historical price, valuation and analyst data - not a person, not a forecast guarantee, and not investment advice.

Factor grades

Ranked against 2849 U.S. stocks StockVane covers.

Last computed: 2026-11-21 14:27 UTC

Data coverage: 4 of 6 factors. Missing data is not a zero score.

Overall B-

The radar needs all six factors. Available grades are shown below.

Valuation N/A

How expensive the stock is versus earnings, sales and its own 5-year history.

Not enough data to grade this factor.

Growth N/A

How fast revenue, profit and free cash flow are compounding.

Not enough data to grade this factor.

Profitability D-

How much profit the business keeps from each dollar of sales and capital.

Return on equity -32.1% Better than 12%
Return on invested capital -36.5% Better than 8%
Momentum C

Recent price strength, skipping the latest month to avoid short-term noise.

3-month return -46.8% Better than 7%
6-month return -16.5% Better than 31%
12-month return (ex latest month) 520.0% Better than 100%
Distance below 52-week high 49.9% Better than 19%
Financial Health A+

Balance-sheet strength: leverage, liquidity and interest coverage.

Current ratio 15.2x Better than 97%
Debt to assets 0.3% Better than 97%
Analyst View A+

What the Street thinks: share of Buy ratings and upside to the average target.

Analysts rating Buy 100.0% Better than 77%
Upside to average target 217.5% Better than 95%

Grades are relative rankings, not forecasts: A+ is the top 5% of the covered stocks on a factor, F the bottom 3%. Valuation is not adjusted for sector. Background recomputation is scheduled every 6 hours; actual computation time is shown above, and source datasets have different reporting dates. Not investment advice or tailored to your financial situation.

Performance

1W -11.29%
1M -14.91%
3M -46.00%
6M -12.64%
YTD +129.75%
1Y +431.21%
3Y +261.81%
5Y -48.46%

Key statistics

Price & volume

Prev close
9.28
Open
8.98
Day range
8.90 - 9.40
Avg price
9.19
Volume
770.18K
Turnover
7.08M
Amplitude
5.37%
52-week range
1.64 - 18.33

Valuation

P/E
-10.44
P/E (TTM)
-11.35
P/B
2.37
EPS
-0.88
Net profit
-51.69M
Net assets
228.08M

Share structure

Market cap
539.80M
Float cap
339.13M
Shares out
58.74M
Float shares
36.90M

Dividend & listing

Dividend (TTM)
0.00
Listing date
2021-08-10
52-week range 45% of range
1.64 18.33

49.9% below the 52-week high

Trading activity

Net capital flow main funds, last 45 sessions

-7.67M net over the window

Short interest

Shares short
10.61M
As of
2026-10-30

Frequently asked questions

What is the current stock price of Climb Bio (CLYM)?

Climb Bio last traded at 9.19. This page shows a periodic quote snapshot. Check the displayed quote time.

What is Climb Bio's market cap?

About 539.80M.

What is the P/E ratio of Climb Bio?

The trailing twelve-month P/E is -11.35. The Valuation tab shows it against the stock's own five-year range.

Does Climb Bio pay a dividend?

Climb Bio does not currently pay a regular dividend.

Is Climb Bio a buy according to analysts?

The consensus of 12 analysts is a Buy rating, with an average 12-month price target of 29.18, which implies 217.5% upside from the current price. This is not investment advice.

What is Climb Bio's StockVane Quant Rating?

The StockVane Momentum strategy currently rates Climb Bio a D (Sell). Below its 200-day average or in the bottom third on momentum — the strategy is out of it. Not investment advice.

Quote time 2026-11-20 19:30:06 · For reference only, not investment advice and not tailored to your situation.

Climb Bio discussion 0 comments

Add a comment